DK1562985T3 - "Anvendelse af opløselige former af CD83 og nukleinsyrer, der koder for disse, til behandling eller forebyggelse af sygdomme" - Google Patents

"Anvendelse af opløselige former af CD83 og nukleinsyrer, der koder for disse, til behandling eller forebyggelse af sygdomme" Download PDF

Info

Publication number: DK1562985T3
Authority: DK; Denmark
Prior art keywords: diseases; prevention; treatment; nucleic acids; acids encoding
Prior art date: 2002-11-19

Application number

DK03767573.3T

Other languages

English (en)

Inventor

Alexander Steinkasserer

Matthias Lechmann

Elisabeth Zinser

Original Assignee

Argos Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-19

Filing date

2003-11-19

Publication date

2015-04-13

2003-11-19 Application filed by Argos Therapeutics Inc filed Critical Argos Therapeutics Inc

2015-04-13 Application granted granted Critical

2015-04-13 Publication of DK1562985T3 publication Critical patent/DK1562985T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Virology (AREA)
Dermatology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Hematology (AREA)

DK03767573.3T 2002-11-19 2003-11-19 "Anvendelse af opløselige former af CD83 og nukleinsyrer, der koder for disse, til behandling eller forebyggelse af sygdomme" DK1562985T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02025851A EP1422241A1 (en)	2002-11-19	2002-11-19	Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
PCT/EP2003/012941 WO2004046182A2 (en)	2002-11-19	2003-11-19	Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases

Publications (1)

Publication Number	Publication Date
DK1562985T3 true DK1562985T3 (da)	2015-04-13

Family

ID=32187165

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03767573.3T DK1562985T3 (da)	2002-11-19	2003-11-19	"Anvendelse af opløselige former af CD83 og nukleinsyrer, der koder for disse, til behandling eller forebyggelse af sygdomme"

Country Status (9)

Country	Link
US (3)	US7893200B2 (da)
EP (5)	EP1422241A1 (da)
JP (3)	JP4740595B2 (da)
AU (1)	AU2003292045A1 (da)
CA (2)	CA2847795C (da)
DK (1)	DK1562985T3 (da)
ES (2)	ES2413631T3 (da)
SI (1)	SI1562985T1 (da)
WO (1)	WO2004046182A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1422241A1 (en)	2002-11-19	2004-05-26	Alexander Steinkasserer	Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US7169898B2 (en)	2002-12-04	2007-01-30	Alexander Steinkasserer	Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US9102726B2 (en)	2002-12-04	2015-08-11	Argos Therapeutics, Inc.	Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
JP5570808B2 (ja) *	2006-08-18	2014-08-13	アルゴス・セラピューティクス・インコーポレーテッド	併用療法におけるｃｄ８３の使用
US8513208B2 (en)	2008-02-28	2013-08-20	Argos Therapeutics, Inc.	Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
EP2288387B1 (en) *	2008-05-23	2013-02-13	Argos Therapeutics, Inc.	Novel soluble cd83 polypeptides, formulations and methods of use
EP2497498A4 (en)	2009-11-05	2013-04-17	Univ Osaka	THERAPEUTIC ACTIVE FOR AUTOIMMUNE DISEASES OR ALLERGIES AND METHOD FOR SCREENING AFTER THE THERAPEUTIC ACTIVE SUBSTANCE
CN109369807B (zh) *	2015-01-27	2021-07-27	中国科学技术大学先进技术研究院	抗人cd83单克隆抗体及其制备、鉴定和应用
JP7228824B2 (ja)	2015-06-30	2023-02-27	国立大学法人大阪大学	抗プレキシンａ１アゴニスト抗体
EP3534960A4 (en)	2016-11-07	2020-05-13	Coimmune, Inc.	SPECIFIC ANTIBODIES MODULATING AND USING THE TLR-4 SIGNALING
KR102679493B1 (ko)	2017-01-31	2024-07-01	킴벌리-클라크 월드와이드, 인크.	벤조산 에스테르를 포함하는 항균 조성물 및 이를 이용한 세균 생장 억제 방법
EP3895723A1 (en)	2020-04-16	2021-10-20	Friedrich-Alexander-Universität Erlangen-Nürnberg	Scd83 for wound healing, hair growth, and skin and hair care
DE102024110866A1 (de) *	2024-04-18	2025-10-23	Christian Arnold	Pharmazeutische Zusammensetzung zur Heilung einer Wunde

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5710262A (en)	1992-04-17	1998-01-20	Dana-Faber Cancer Institute, Inc.	Nucleic acid encoding HB15 polypeptides
US5316920A (en) *	1992-04-17	1994-05-31	Dana-Faber Cancer Institute, Inc.	Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
AU2273397A (en) *	1996-02-15	1997-09-02	Immunex Corporation	Methods and compositions for modulating an immune response
CN1272884A (zh)	1997-08-26	2000-11-08	津莫吉尼蒂克斯公司	脂肪细胞特异性蛋白质同系物
EP1176981B1 (en)	1999-05-07	2005-11-30	Genentech, Inc.	Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
GB2370273A (en)	2000-12-20	2002-06-26	Viaxxel Biotech Gmbh	Compounds that affect CD83 expression
EP1436319A2 (en) *	2001-10-18	2004-07-14	Zlatko Ademovic	Repetitive motifs from salivary proline rich proteins, mucin and collagen
WO2003045318A2 (en)	2001-11-21	2003-06-05	Celltech R & D, Inc.	Manipulation of cytokine levels using cd83 gene products
US20040185040A1 (en)	2001-11-21	2004-09-23	Celltech R & D Limited	Modulating immune responses
US6652537B2 (en)	2001-12-12	2003-11-25	C. R. Bard, Inc.	Articulating stone basket
US20030219436A1 (en)	2002-03-15	2003-11-27	Ledbetter Jeffrey A.	Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
AU2002950779A0 (en)	2002-08-15	2002-09-12	The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland	A method of immunomodulation
US20050032725A1 (en)	2002-10-09	2005-02-10	Toerrx, Inc.	Molecules preferentially associated with effector T cells or regulatory T cells and methods of their use
EP1422241A1 (en)	2002-11-19	2004-05-26	Alexander Steinkasserer	Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US7169898B2 (en)	2002-12-04	2007-01-30	Alexander Steinkasserer	Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US9102726B2 (en)	2002-12-04	2015-08-11	Argos Therapeutics, Inc.	Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
EP2288387B1 (en)	2008-05-23	2013-02-13	Argos Therapeutics, Inc.	Novel soluble cd83 polypeptides, formulations and methods of use

2002
- 2002-11-19 EP EP02025851A patent/EP1422241A1/en not_active Withdrawn
2003
- 2003-11-19 ES ES10188586T patent/ES2413631T3/es not_active Expired - Lifetime
- 2003-11-19 CA CA2847795A patent/CA2847795C/en not_active Expired - Lifetime
- 2003-11-19 WO PCT/EP2003/012941 patent/WO2004046182A2/en not_active Ceased
- 2003-11-19 EP EP03767573.3A patent/EP1562985B1/en not_active Expired - Lifetime
- 2003-11-19 EP EP13189881.9A patent/EP2692733B1/en not_active Expired - Lifetime
- 2003-11-19 EP EP15195041.7A patent/EP3031824A1/en not_active Withdrawn
- 2003-11-19 ES ES03767573.3T patent/ES2534308T3/es not_active Expired - Lifetime
- 2003-11-19 CA CA2507373A patent/CA2507373C/en not_active Expired - Lifetime
- 2003-11-19 EP EP10188586A patent/EP2345670B1/en not_active Expired - Lifetime
- 2003-11-19 DK DK03767573.3T patent/DK1562985T3/da active
- 2003-11-19 AU AU2003292045A patent/AU2003292045A1/en not_active Abandoned
- 2003-11-19 US US10/535,522 patent/US7893200B2/en active Active
- 2003-11-19 SI SI200332422T patent/SI1562985T1/sl unknown
- 2003-11-19 JP JP2004552655A patent/JP4740595B2/ja not_active Expired - Lifetime
2011
- 2011-01-21 US US13/011,380 patent/US8759505B2/en not_active Expired - Lifetime
- 2011-02-07 JP JP2011023799A patent/JP5557765B2/ja not_active Expired - Lifetime
2014
- 2014-04-24 JP JP2014090480A patent/JP5878584B2/ja not_active Expired - Lifetime
- 2014-06-17 US US14/306,712 patent/US9732140B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2847795A1 (en)	2004-06-03
US20120015890A1 (en)	2012-01-19
EP1562985A2 (en)	2005-08-17
ES2413631T3 (es)	2013-07-17
SI1562985T1 (sl)	2015-05-29
US7893200B2 (en)	2011-02-22
WO2004046182A2 (en)	2004-06-03
EP2345670A1 (en)	2011-07-20
JP5557765B2 (ja)	2014-07-23
US20150065684A1 (en)	2015-03-05
EP2345670B1 (en)	2013-03-20
US20070167607A1 (en)	2007-07-19
CA2847795C (en)	2018-05-01
US8759505B2 (en)	2014-06-24
AU2003292045A8 (en)	2004-06-15
CA2507373C (en)	2014-06-10
EP1422241A1 (en)	2004-05-26
AU2003292045A1 (en)	2004-06-15
EP2692733B1 (en)	2015-11-18
EP1562985B1 (en)	2015-01-07
WO2004046182A3 (en)	2004-10-14
US9732140B2 (en)	2017-08-15
JP2011144177A (ja)	2011-07-28
HK1194400A1 (en)	2014-10-17
EP2692733A1 (en)	2014-02-05
JP2006523432A (ja)	2006-10-19
JP4740595B2 (ja)	2011-08-03
JP5878584B2 (ja)	2016-03-08
HK1079220A1 (en)	2006-03-31
JP2014195455A (ja)	2014-10-16
CA2507373A1 (en)	2004-06-03
ES2534308T3 (es)	2015-04-21
EP3031824A1 (en)	2016-06-15

Publication	Publication Date	Title
DK1427437T3 (da)	2013-03-04	Oxyntomodulin til forebyggelse eller behandling af overvægt
IS8267A (is)	2006-01-26	[1,8]naftýridín-2-ón og tengd efnasambönd til notkunar við meðferð á geðklofa
DK1506041T3 (da)	2008-01-28	Inbandronsyre til behandling og forebyggelse af osteoporose
IS7684A (is)	2005-02-03	Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
ATE315938T1 (de)	2006-02-15	4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
DE60230425D1 (de)	2009-01-29	Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE50303749D1 (de)	2006-07-20	Verfahren zur herstellung von phthalocyaninpigmentzubereitungen
DK1487541T3 (da)	2009-01-19	Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
DK1342881T3 (da)	2006-10-23	Opskummet syrebehandlingsvæske
NO20051503D0 (no)	2005-03-21	Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
DK1562985T3 (da)	2015-04-13	"Anvendelse af opløselige former af CD83 og nukleinsyrer, der koder for disse, til behandling eller forebyggelse af sygdomme"
DK1537140T3 (da)	2013-04-15	Nukleinsyre og tilsvarende protein betegnet 161P2F10B, der er anvendelige i behandling og detektering af cancer
IS7163A (is)	2004-02-26	Aðferðir til meðhöndlunar á lungnasjúkdómi
DK1372719T3 (da)	2013-01-21	Nukleinsyre og tilsvarende protein betegnet 125P5C8, der er anvendelig i behandling og påvisning af cancer
DK1355668T3 (da)	2008-05-05	Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
DK1245613T3 (da)	2005-09-05	Fremgangsmåde til fremstilling af tannin samt dets anvendelse
DK1461042T3 (da)	2008-12-01	Anvendelse af desoxypeganin til behandling af klinisk depression
DE50302933D1 (de)	2006-05-24	Beschichtungsmaterial, Verwendung desselben sowie Verfahren zur Aufbringung des Beschichtungsmaterials
NO20010345L (no)	2002-07-22	Fremgangsmåte og anordning til behandling av gasser, samt anvendelse derav
DK1466604T3 (da)	2008-03-03	Isoquinolinderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf ved behandling af metatoninerge problemsystemer
DK1341758T3 (da)	2006-10-30	Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme
DK1318142T3 (da)	2007-08-20	t-butoxycarbonylaminoethylamin til syntese af PNA-monomerenheder, aminosyrederivater, mellemprodukter deraf og fremgangsmåder til fremstilling af disse
IS7624A (is)	2004-12-29	Aðferð við losun íláts, og notkun þeirrar aðferðar
DK1263423T3 (da)	2006-12-11	Præparat til forebyggelse og/eller behandling af vaskulære sygdomme bestående af propionyl-L-carnitin og coenzym Q10
DE60137912D1 (de)	2009-04-23	Prozessor und Verfahren zum Steuern der Rückstellungssequenz des Prozessors